SeekingAlpha · Nov 10, 2026
Harrow, Inc. (HROW) Q3 2026 Earnings Call Transcript
Harrow, Inc. (HROW) Q3 2026 Earnings Call November 10, 2026 8:00 AM ESTCompany ParticipantsMichael Biega - Vice President of Investor Relations &...
NASDAQ · HROW
Healthcare · Drug Manufacturers - Specialty & Generic
$29.09
Down-$1.03 (-3.42%)
Updated Nov 17, 2026, 4:11 AM
SID Score
4.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · HROW
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 16, 2026
HROW closed at $29.09 after 21 trading sessions, up 5.09% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 16, 2026 | $29.65 | $30.39 | $29.00 | $29.09 | 474.25K |
| Nov 13, 2026 | $28.37 | $31.10 | $28.31 | $30.12 | 736.43K |
| Nov 12, 2026 | $29.54 | $29.54 | $28.16 | $28.30 | 551.15K |
| Nov 11, 2026 | $29.88 | $30.5158 | $28.60 | $29.37 | 979.49K |
| Nov 10, 2026 | $33.065 | $33.6799 | $28.9114 | $30.36 | 2.15M |
| Nov 9, 2026 | $27.05 | $27.84 | $26.1432 | $27.47 | 1.17M |
| Nov 6, 2026 | $26.40 | $26.94 | $25.76 | $26.89 | 650.86K |
| Nov 5, 2026 | $28.71 | $28.71 | $25.97 | $26.04 | 701.97K |
| Nov 4, 2026 | $28.41 | $29.535 | $28.38 | $28.75 | 778.03K |
| Nov 3, 2026 | $28.21 | $28.98 | $27.81 | $28.54 | 625.37K |
| Nov 2, 2026 | $28.38 | $28.91 | $27.29 | $28.20 | 742.63K |
| Oct 30, 2026 | $29.69 | $30.05 | $28.0825 | $28.24 | 335.28K |
| Oct 29, 2026 | $29.90 | $30.28 | $29.6058 | $29.99 | 321.08K |
| Oct 28, 2026 | $28.96 | $29.74 | $28.70 | $29.39 | 327.33K |
| Oct 27, 2026 | $29.10 | $29.57 | $28.435 | $29.07 | 635.45K |
| Oct 26, 2026 | $28.61 | $29.48 | $28.30 | $28.95 | 499.15K |
| Oct 23, 2026 | $27.76 | $28.555 | $27.14 | $28.44 | 854.71K |
| Oct 22, 2026 | $27.82 | $28.45 | $27.702 | $28.15 | 440.12K |
| Oct 21, 2026 | $28.26 | $28.66 | $27.98 | $28.24 | 524.42K |
| Oct 20, 2026 | $27.70 | $29.25 | $27.70 | $28.07 | 526.97K |
| Oct 19, 2026 | $27.40 | $28.53 | $27.40 | $27.68 | 576.13K |
The latest Smart Investors Daily articles mentioning HROW.
Company
Market Activity
Research & News
HROW research
Company profile and research snapshot.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 11, 2026 | BTIG | Buy | — |
| Oct 7, 2026 | BTIG | Buy | — |
| Sep 9, 2026 | Leerink Partners | Outperform | — |
| Aug 11, 2026 | BTIG | Buy | — |
| Jul 21, 2026 | BTIG | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Nov 10, 2026
Harrow, Inc. (HROW) Q3 2026 Earnings Call November 10, 2026 8:00 AM ESTCompany ParticipantsMichael Biega - Vice President of Investor Relations &...
Yahoo · Nov 9, 2026
Although the revenue and EPS for Harrow (HROW) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Yahoo · Nov 9, 2026
(HROW) on Monday reported third-quarter net income of $9.The Nashville, Tennessee-based company said it had profit of 25 cents per share.
Yahoo · Nov 9, 2026
Third Quarter 2026 and Selected Highlights: Record third quarter revenue of $99.3 million, up 41% sequentially and 39% year over yearBranded revenue of $83.5 million, up 62% year over year and approximately 84% of total revenueGAAP net income of $9.8 million, including a $5.0 million litigation settlement gain, compared with a net loss of $17.3 million in the second quarter of 2026 and net income of $1.0 million in the third quarter of 2025Adjusted EBITDA (a non-GAAP measure) of $21.2 million, c
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning HROW.